EMPLOYMENT AGREEMENTEmployment Agreement • March 14th, 2024 • Eterna Therapeutics Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledMarch 14th, 2024 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (this “Agreement”) is made as of the 1st day of January, 2024 (the “Effective Date”) between Eterna Therapeutics, Inc. f/k/a Brooklyn Immuno Therapeutics, Inc. (the “Company”) and Dorothy Clarke (“Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 14th, 2023 • GRI BIO, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 14th, 2023 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (this “Agreement”) is made as of the 1st day of July, 2023 (the “Effective Date”), between GRI Bio, Inc. (the “Company”) and Albert Agro, PhD. (“Executive”), and shall become effective on the date provided herein.
EMPLOYMENT AGREEMENTEmployment Agreement • February 24th, 2023 • Vallon Pharmaceuticals, Inc. • Pharmaceutical preparations • California
Contract Type FiledFebruary 24th, 2023 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (this “Agreement”) is made as of the 20th day of February, 2023, between GRI Bio, Inc. (the “Company”) Vipin Kumar Chaturvedi (“Executive”), and shall become effective on the date provided herein.
EMPLOYMENT AGREEMENTEmployment Agreement • February 24th, 2023 • Vallon Pharmaceuticals, Inc. • Pharmaceutical preparations • California
Contract Type FiledFebruary 24th, 2023 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (this “Agreement”) is made as of the 20th day of February, 2023, between GRI Bio, Inc. (the “Company”) and Marc Hertz, Ph.D (“Executive”), and shall become effective on the date provided herein.
EMPLOYMENT AGREEMENTEmployment Agreement • February 24th, 2023 • Vallon Pharmaceuticals, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledFebruary 24th, 2023 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (this “Agreement”) is made as of the 20th day of February, 2023, between GRI Bio, Inc. (the “Company”) and Leanne M. Kelly (“Executive”), and shall become effective on the date provided herein.